Severity of chronic obstructive pulmonary disease with 'exacerbator with emphysema phenotype' is associated with potential biomarkers
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ..
OBJECTIVE: The present study was designed to investigate the biomarkers levels of fractalkine (FKN), neutrophil elastase (NE) and matrix metalloproteinase-12 (MMP-12) in chronic obstructive pulmonary disease (COPD) with 'exacerbator with emphysema phenotype' and to evaluate the associations between the biomarkers levels and the severity of disease by spirometric measurements.
METHODS: A total of 84 COPD patients and 49 healthy controls were enrolled in our study. ELISA were utilised to detect the FKN, MMP-12 and NE in serum from all subjects.
RESULTS: FKN (p<0.001), NE (p=0.039) and MMP-12 (p<0.001) in serum of COPD patients showed higher levels than that of healthy control subjects. Serum FKN (p<0.001), MMP-12 (p<0.001) and NE (p=0.043) levels were significantly higher in severe and very severe COPD patients than that in mild and moderate COPD patients. Circulating FKN, MMP-12 and NE expression levels were significantly elevated (p<0.001) in COPD smokers compared with COPD non-smokers. The smoke pack years were negatively correlated with FEV1%pred (r=-0.5036), FEV1/FVC ratio (r=-0.2847) (FEV, forced expiratory volume; FVC, forced vital capacity). Similarly, we observed a strong positive correlation between the smoke pack years and serum levels of FKN (r=0.4971), MMP-12 (r=0.4315) and NE (r=0.2754). FEV1%pred was strongly negatively correlated with cytokine levels of FKN (r=-0.4367), MMP-12 (r=-0.3295) and NE (r=-0.2684). Likewise, FEV1/FVC ratio was negatively correlated with mediators of inflammation levels of FKN (r=-0.3867), MMP-12 (r=-0.2941) and NE (r=-0.2153).
CONCLUSION: Serum FKN, MMP-12 and NE concentrations in COPD patients are directly associated with the severity of COPD with 'exacerbator with emphysema phenotype'. This finding suggests that FKN, MMP-12 and NE might play an important role in the pathophysiology of COPD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:96 |
|---|---|
| Enthalten in: |
Postgraduate medical journal - 96(2020), 1131 vom: 30. Jan., Seite 28-32 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hao, Wendong [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 03.06.2020 Date Revised 03.06.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1136/postgradmedj-2019-136599 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM299868567 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM299868567 | ||
| 003 | DE-627 | ||
| 005 | 20231225101259.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/postgradmedj-2019-136599 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0999.xml |
| 035 | |a (DE-627)NLM299868567 | ||
| 035 | |a (NLM)31375557 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hao, Wendong |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Severity of chronic obstructive pulmonary disease with 'exacerbator with emphysema phenotype' is associated with potential biomarkers |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.06.2020 | ||
| 500 | |a Date Revised 03.06.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a OBJECTIVE: The present study was designed to investigate the biomarkers levels of fractalkine (FKN), neutrophil elastase (NE) and matrix metalloproteinase-12 (MMP-12) in chronic obstructive pulmonary disease (COPD) with 'exacerbator with emphysema phenotype' and to evaluate the associations between the biomarkers levels and the severity of disease by spirometric measurements | ||
| 520 | |a METHODS: A total of 84 COPD patients and 49 healthy controls were enrolled in our study. ELISA were utilised to detect the FKN, MMP-12 and NE in serum from all subjects | ||
| 520 | |a RESULTS: FKN (p<0.001), NE (p=0.039) and MMP-12 (p<0.001) in serum of COPD patients showed higher levels than that of healthy control subjects. Serum FKN (p<0.001), MMP-12 (p<0.001) and NE (p=0.043) levels were significantly higher in severe and very severe COPD patients than that in mild and moderate COPD patients. Circulating FKN, MMP-12 and NE expression levels were significantly elevated (p<0.001) in COPD smokers compared with COPD non-smokers. The smoke pack years were negatively correlated with FEV1%pred (r=-0.5036), FEV1/FVC ratio (r=-0.2847) (FEV, forced expiratory volume; FVC, forced vital capacity). Similarly, we observed a strong positive correlation between the smoke pack years and serum levels of FKN (r=0.4971), MMP-12 (r=0.4315) and NE (r=0.2754). FEV1%pred was strongly negatively correlated with cytokine levels of FKN (r=-0.4367), MMP-12 (r=-0.3295) and NE (r=-0.2684). Likewise, FEV1/FVC ratio was negatively correlated with mediators of inflammation levels of FKN (r=-0.3867), MMP-12 (r=-0.2941) and NE (r=-0.2153) | ||
| 520 | |a CONCLUSION: Serum FKN, MMP-12 and NE concentrations in COPD patients are directly associated with the severity of COPD with 'exacerbator with emphysema phenotype'. This finding suggests that FKN, MMP-12 and NE might play an important role in the pathophysiology of COPD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a FKN | |
| 650 | 4 | |a chronic obstructive pulmonary disease | |
| 650 | 4 | |a exacerbator with emphysema phenotype | |
| 650 | 4 | |a matrix metalloproteinase-12 | |
| 650 | 4 | |a neutrophil elastase | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Chemokine CX3CL1 |2 NLM | |
| 650 | 7 | |a Leukocyte Elastase |2 NLM | |
| 650 | 7 | |a EC 3.4.21.37 |2 NLM | |
| 650 | 7 | |a Matrix Metalloproteinase 12 |2 NLM | |
| 650 | 7 | |a EC 3.4.24.65 |2 NLM | |
| 700 | 1 | |a Li, Manxiang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yunqing |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Cailian |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Ping |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Postgraduate medical journal |d 1925 |g 96(2020), 1131 vom: 30. Jan., Seite 28-32 |w (DE-627)NLM000043753 |x 1469-0756 |7 nnns |
| 773 | 1 | 8 | |g volume:96 |g year:2020 |g number:1131 |g day:30 |g month:01 |g pages:28-32 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/postgradmedj-2019-136599 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 96 |j 2020 |e 1131 |b 30 |c 01 |h 28-32 | ||